Clinical trials: Bacterial Vaginosis (BV)
Randomized, Open-label
A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)
A randomized, multicenter, open-label, active-controlled Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of multiple intravaginal doses of GenSci142 in patients with bacterial…
- Conditions
- Randomized, Open-label, Safety, Tolerability
- Trial name
- NCT07663838
- Testing
- GenSci142 capsule, clindamycin phosphate vaginal cream
- Where
- 9 sites in China
- Volunteers
- 42 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Bacterial Vaginosis
A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
The primary objective of the study is to assess the efficacy of 1% SPL7013 Gel compared to placebo gel for the treatment of bacterial vaginosis (BV).
- Trial name
- NCT01577238
- Testing
- 1% SPL7013 Gel
- Volunteers
- 250 people
- Sponsor
- Starpharma Pty Ltd
Bacterial Vaginosis
Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
A double-blind, phase 3 study to determine the efficacy of SPL7013 Gel when administered on alternate days for 16 weeks, compared to placebo gel in preventing the recurrence of BV in women with a history of recurrent BV.
- Trial name
- NCT02237950
- Testing
- Metronidazole oral tablets 500mg, 1% SPL7013 Gel
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 586 people
- Sponsor
- Starpharma Pty Ltd
Bacterial Vaginosis (BV)
WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial enrolling approximately 150 pre-menopausal women with bacterial vaginosis (BV). Participants will be randomized 1:1:1 to three groups.
- Trial name
- NCT07888699
- Testing
- High-dose WST03 Vaginal Capsule Metronidazole, Low-dose WST03 Vaginal Capsule Metronidazole
- Where
- 14 sites in China
- Volunteers
- 150 people
- Sponsor
- SPH Sine Pharmaceutical Laboratories Co., Ltd.
Bacterial Vaginoses
Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV
A multi-center, open-label study to evaluate the treatment of one oral dose of 2g Solosec™ (Secnidazole) in adolescent girls with BV
- Trial name
- NCT03937869
- Testing
- Secnidazole
- Where
- 9 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lupin Research Inc
Bacterial Vaginosis (BV)
Efficacy and Safety of Vaginal Lactobacillus Dual Probiotic Capsules in Bacterial Vaginosis
Primary Objective: To confirm that the clinical cure rate of Vaginal Lactobacillus Dual Probiotic Capsules for bacterial vaginosis (BV) is superior to placebo at the 21-30 day post-treatment visit (Day 21 to Day 30).
- Trial name
- BV (NCT07418957)
- Testing
- Vaginal Lactobacillus Dual Probiotic Capsules
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Guangdong Longchuangji Pharmaceutical Co., Ltd.
Bacterial Vaginosis
A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
The primary objective of the study is to assess the efficacy of 1% SPL7013 Gel compared to placebo gel for the treatment of bacterial vaginosis (BV).
- Trial name
- NCT01577537
- Testing
- 1% SPL7013 Gel
- Volunteers
- 251 people
- Sponsor
- Starpharma Pty Ltd
Vaginosis, Bacterial
Safety, Tolerability and Efficacy of Vaginal Suppository WO3191 in the Post-treatment of Bacterial Vaginosis
Bacterial Vaginosis (BV) is a common infectious disorder and is characterized by a disturbance in the vaginal microbiological milieu.
- Trial name
- NCT02687789
- Testing
- Medical Device: WO3191, Medical Device: Vagisan® Lactic Acid
- Where
- 13 sites in Germany
- Volunteers
- 43 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Bacterial Vaginosis (BV)
An Open Single-armed Investigation to Evaluate the Safety of pHyph Following a Prolonged Treatment Duration in Adult Women With Bacterial Vaginosis
1. Rationale Bacterial vaginosis (BV) is caused by an overgrowth of bacteria and affects most women at some point. The infections can cause foul-smelling discharge and sometimes itching and burning.
- Trial name
- NCT07394777
- Testing
- pHyph
- Where
- 2 sites in Sweden
- Volunteers
- 32 people
- Sponsor
- Gedea Biotech AB
Recurrent Bacterial Vaginosis (BV)
Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV)
The purpose in this clinical study is to determine the efficacy of SPL7013 Gel for the prevention of recurrence of bacterial vaginosis.
- Trial name
- NCT01437722
- Testing
- 1% SPL7013 Gel, 3% SPL7013 Gel
- Volunteers
- 205 people
- Sponsor
- Starpharma Pty Ltd